Page last updated: 2024-08-23

daunorubicin and oblimersen

daunorubicin has been researched along with oblimersen in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bloomfield, CD; Blum, W; Byrd, JC; Chan, KK; Dai, G; Green, M; Grever, MR; Kefauver, C; Klisovic, MI; Klisovic, RB; Larson, RA; Liu, S; Maharry, K; Marcucci, G; Moran, M; Novick, S; Sher, DA; Stock, W; Zwiebel, JA	1
Døskeland, SO; Herfindal, L; Oftedal, L; Selheim, F; Sivonen, K; Wahlsten, M	1

Trials

1 trial(s) available for daunorubicin and oblimersen

Article	Year
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides, Antisense; Probability; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Thionucleotides; Treatment Outcome	2005

Article

Year

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides, Antisense; Probability; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Thionucleotides; Treatment Outcome

2005

Other Studies

1 other study(ies) available for daunorubicin and oblimersen

Article	Year
Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes. Marine drugs, 2010, Oct-14, Volume: 8, Issue:10 Topics: Adaptor Proteins, Signal Transducing; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood Platelets; Cardiotonic Agents; Caspases; Cell Line, Tumor; Cyanobacteria; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Hepatocytes; Leukemia, Myeloid, Acute; Myocytes, Cardiac; Rats; Seawater; Thionucleotides; Transcription Factors	2010

Article

Year

Marine benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill leukemia cells, but not cardiomyocytes.

Marine drugs, 2010, Oct-14, Volume: 8, Issue:10

Topics: Adaptor Proteins, Signal Transducing; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood Platelets; Cardiotonic Agents; Caspases; Cell Line, Tumor; Cyanobacteria; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Hepatocytes; Leukemia, Myeloid, Acute; Myocytes, Cardiac; Rats; Seawater; Thionucleotides; Transcription Factors

2010